Therapeutic drug monitoring of netilmicin by the Sawchuk-Zaske method in 10 patients with respiratory infection.
スポンサーリンク
概要
- 論文の詳細を見る
Multiple-infusion dosing strategies for netilmicin were established for 10 patients using the Sawchuk-Zaske method (individually calculated values of elimination kinetic parameters). A test dose of netilmicin was adminstered to each patient by constant-rate infusion, usually over a 60-min period.<BR>Serum was drawn at 1, 3 and 6 hours of the postinfusion phase. All samples were immediately analyzed for netilmicin by a fluorescence polarization immunoassay (FPIA).<BR>The serum level-time data from the postinfusion phase were fitted to a single exponential term using linear regression analysis. Serum level-time data obtained after single infusion were used to determine the patient's netilmicin half-life (mean±SD, 2.54±0.92 h) and distribution volume (mean±SD, 15.62±2.72 h). The mean total body clearance was 5.04±1.97l/h and the mean maximum serum level was 7.46±1.00 μg/ml. The trough level was O.40±0.22 μg/ml. Dosing intervals and the infusion rate were calculated based on each patient's kinetic parameters and the desired steadystate peaks and troughs predicted using a one-compartment pharmacokinetic model. The follow-up steady-state peak and trough levels were similarly measured. All peaks and troughs were within the therapeutic range. No patients suffered side effects.<BR>The mean error (ME), mean absolute error (MAE) and root mean squared error (RMSE) served as measures of accuracy and precision. The ME, MAE and RMSE of peaks and troughs were-0.010, 0.180, 0.253 μg/ml, respectively. The Sawchuk-Zaske method proved to be simple and accurate in calculating routine netilmicin dosage adjustments.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.